ClinicalTrials.gg
RecruitingNCT06647940Updated Oct 22, 2024

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)

A Phase 2 interventional study of Orelabrutinib Oral Tablet and R-CHOP Protocol in Diffuse Large B Cell Lymphoma (DLBCL), sponsored by Sun Yat-sen University. Recruiting at 11 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-22.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse — 9 open to participants now, 9 under way, 2 of them phase 3. orelabrutinib · Lymphoma, Large B-Cell, Diffuse.

Planned enrollment
6th of 11
39 · median 39
Started
2024
with 2 others
Phase 2
8 of 11
6 open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
Sun Yat-sen University

Among the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by planned enrollment, is one of 3 that started in 2024, is one of 8 in phase 2, and was the 9th registered.

Lymphoma, Large B-Cell, Diffuse

1,873 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

9 of the 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

About orelabrutinib

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 265 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 176 (66%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing orelabrutinib in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of orelabrutinib combined with the R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) regimen as first-line treatment in CD5-positive diffuse large B-cell lymphoma (DLBCL) patients.

Read the detailed description

The purpose of this phase II clinical trial is to evaluate the efficacy and safety of orelabrutinib in combination with R-CHOP for untreated CD5-positive DLBCL patients.

The induction phase consisted of 6 cycles of orelabrutinib in combination with R-CHOP (orelabrutinib added from the second cycle), followed by 2 cycles of rituximab + orelabrutinib, for a total of 8 treatment cycles. After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with orelabrutinib will be conducted.

The primary endpoint is the 2-year event-free survival (EFS) rate.

03

Conditions studied

  • Diffuse Large B Cell Lymphoma (DLBCL)

Keywords

  • DLBCL
  • Orelabrutinib
  • CD5-positive
  • R-CHOP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Subjects fully understand and voluntarily participate in this study and sign .
  2. Aged ≥18 years, both male and female.
  3. confirmed CD5-positive DLBCL
  4. There must be at least one measurable or evaluable lesion that meets the evaluation criteria for Lugano 2014 lymphoma.
  5. (ECOG) performance status score of 0-2.
  6. Expected survival ≥3 months.
  7. Sufficient bone marrow, liver, and kidney function.

Key Exclusion Criteria:

  1. DLBCL combined with other types of lymphoma. Transformed DLBCL.
  2. DLBCL with central nervous system invasion.
  3. The patients had previously received BTK inhibitors.
  4. The patients have to any drug in the combined treatment.
  5. Patients with the infection of (HIV) and/or acquired immunodeficiency syndrome.
  6. Inability to swallow tablets, presence of malabsorption syndrome, or any other gastrointestinal disease or dysfunction that may affect the absorption of the study drug.
  7. Pregnant and lactating women, and subjects of childbearing age who do not want to use .
  8. Mentally ill persons or persons unable to obtain informed consent.
  9. The investigators think that the patient is not suitable for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (estimated)

Study arms

  • Experimental
    Orelabrutinib in combination with R-CHOP

    Patients with CD5 positive diffuse large B-cell lymphoma will receive orelabrutinib in combination with R-CHOP regimen from the second cycle of R-CHOP (3 weeks per cycle). After 8 cycles of induction therapy, if the response is assessed as complete remission (CR), maintenance therapy with orelabrutinib will be conducted.

    Drug: Orelabrutinib Oral Tablet · Drug: R-CHOP Protocol

Interventions

  • DrugOrelabrutinibStudies of OrelabrutinibOrelabrutinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Orelabrutinib (150 mg po D1-D21) is added from the second cycle of R-CHOP regimen

    Also known as: Bruton's Tyrosine Kinase Inhibitor

  • Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone

    Also known as: R-CHOP regimen

06

What researchers measure

Primary outcomes

  1. 2-year event-free survival (EFS) rate

    To investigate the preliminary anti-tumor efficacy

    Time frame: Defined as the proportion of patients without disease progression, treatment discontinuation, or death for any reason within 24 months of enrollment

Secondary outcomes

  1. Complete response rate (CRR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 8 cycles (each cycle is 21 days)

  2. Disease-free survival (DFS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From date of the first complete response until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  3. Objective response rate (ORR)

    To investigate the preliminary anti-tumor efficacy

    Time frame: Up to 8 cycles (each cycle is 21 days)

  4. Progression-free survival (PFS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 24 months

  5. Overall survival (OS)

    To investigate the preliminary anti-tumor efficacy

    Time frame: From the date of enrollment until the date of death from ant cause, assessed up to 24 months

  6. Number of participants with adverse events (AE) and severe adverse events (SAE) as assessed by CTCAE v5.0

    To identify the incidence of AE and SAE

    Time frame: Through study completion, an average of 2 years

Other outcomes

  1. The correlation of gene mutations and alterations in relevant signaling pathways with the efficacy and survival in CD5-positive DLBCL

    To explore the correlations between gene mutations and response and prognosis

    Time frame: Through study completion, an average of 2 years

07

Study locations

11 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2024; primary completion for Nov 2026, 24 months later.

Of 211 non-industry phase 2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 96. This study's planned 24 months is below that.

Counting every sponsor, half of 264 studies reached it within 52 months; a quarter within 35 and three quarters within 85.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2024
First posted
Oct 18, 2024
StartEst.
Nov 1, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
Mar 1, 2027
Last update
Oct 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06647940
Collaborators
Fifth Affiliated Hospital, Sun Yat-Sen University, Gansu Cancer Hospital, First Affiliated Hospital of Shantou University Medical College, Southern Medical University, China, Guangdong Provincial Hospital of Traditional Chinese Medicine, Second Affiliated Hospital of Guangzhou Medical University, Fifth Affiliated Hospital of Guangzhou Medical University, Shenzhen People's Hospital, Guangzhou First People's Hospital, Dongguan People's Hospital, The First People's Hospital of Zhaoqing
Responsible party
Qingqing Cai (chief physician, Sun Yat-sen University) — Principal investigator
First posted
Oct 18, 2024
Start date
Nov 1, 2024 (estimated)
Primary completion
Nov 1, 2026 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Oct 22, 2024

Study contacts

Qingqing Cai, MD. PhD.
Contact
caiqq@sysucc.org.cn
02087342823
Yi Xia, MD. PhD.
Contact
xiayi@sysucc.org.cn
02087342823

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Orelabrutinib · R-CHOP protocol

Start the discussion